Table 4.
Clinical characteristics of obese subjects according to anti-apoA-1 IgG status.
| Obese Patients (n = 43) | |||
|---|---|---|---|
| Anti-apoA-1 IgG positive patients | Anti-apoA-1 IgG negative patients | P value | |
| (n = 6) | (n = 37) | ||
| Age, years | 47.5 (39–59) | 43 (34.5–54) | 0.23 |
| Male gender; % (n) | 67 (4) | 57 (21) | 1 |
| Total Cholesterol, mg/dL | 156.0 (124.8–175.5) | 198.9 (175.5–230.1) | 0.008 |
| LDL Cholesterol, mg/dL | 87.2 (70.2–113.1) | 127.9 (102.6–150.2) | 0.01 |
| HDL Cholesterol, mg/dL | 45.2 (43.7–46.0) | 40.9 (37.4–46.8) | 0.24 |
| Triglycerides, mg/dL | 62.7 (43.6–117.5) | 124.6 (96.1–189.0) | 0.01 |
| Glucose, mg/dL | 90.5 (86.5–108.1) | 100.9 (91.9–108.1) | 0.23 |
| Insulin, mU/L | 5.2 (5.2–8.3) | 12.7 (7.3–21.6) | 0.11 |
| HOMA | 1.22 (1.11–1.93) | 3.59 (1.77–5.56) | 0.15 |
| HbA1C, % | 5.4 (5.3–5.5) | 5.4 (5.1–5.7) | 0.92 |
| Hs-CRP, mg/L | 4.0 (1.5–13.1) | 5.2 (2.9–8.5) | 0.69 |
| Framingham Risk Score (FRS) | 2.5 (0.9–5) | 2.0 (0.9–4) | 0.80 |
| BMI, kg/m2 | 32.2 (31.6–32.8) | 42.0 (34.1–45.3) | 0.08 |
| Waist | 116 (114–120) | 119 (111–124) | 0.86 |
| Waist to hip ratio | 0.98 (0.89–1.03) | 0.96 (0.91–0.98) | 0.53 |
| Total fat, Kg | 34.1 (27.3–39.9) | 45.4 (32.9–58.6) | 0.12 |
| Percent of body fat | 34.9 (24.8–40.5) | 38.7 (30.1–47.9) | 0.17 |
| *Agatston score | 2.05 (0–23.2; 0–38.3) | 0(0-0;0–77.1) | 0.003 |
| Subjects with significant coronary lesion; % (n) | 67 (4) | 5 (2) | 0.001 |
| Myocardial blood flow (MBF); | |||
| (mL/min/g): |
|||
| At rest | 0.76 (0.55–0.79) | 0.79 (0.66–0.93) | 0.16 |
| Normalized at rest | 1.01(0.89–1.20) | 0.92 (0.84–1.13) | 0.42 |
| During CPT | 0.80 (0.71–1.13) | 0.87 (0.76–0.95) | 0.65 |
| ΔMBF (CPT-rest) | 0.16 (0.07–0.34) | 0.09 (0.03–0.16) | 0.16 |
| Normalized during CPT | 0.92 (0.81–1.21) | 0.76 (0.67–0.88) | 0.05 |
| During hyperemia | 2.12 (1.40–2.61) | 2.11 (1.78–2.37) | 0.85 |
| Myocardial flow reserve; (mL/min/g) | 2.92 (2.38–3.30) | 2.62 (2.13–3.20) | 0.62 |
| MBF hyperemia/NMBF rest | 2.14 (1.41–2.18) | 2.13 (1.81–2.67) | 0.56 |
| Coronary vascular resistance | |||
| (CVR); (mmHg/mL/mL/g) | |||
| At rest | 113.3 (90.3–132.1) | 112.7 (97.1–134.3) | 0.89 |
| During CPT | 119.7 (81.1–140) | 128.2 (110.0–139.4) | 0.49 |
| ΔCVR (CPT-rest) | −3.25 (−9.17–7.95) | 5.86 (−5.06–18.04) | 0.59 |
| In response to DP | 40.6 (28.9–53.6) | 42.8 (37.2–53.4) | 0.17 |
| Coronary endothelial dysfunction | |||
| ΔMBF to CPT < 0.3, % (n) | 67 (4) | 97 (36) | 0.05 |
Values are median (Q1, Q3), at the exception of *represented as (Q1–Q3; and range). P values according to Mann-Whitney U test for continuous values and to exact bilateral Fischer test for proportions.